Promising trial shows encouraging results for soft tissue sarcoma treatment
A combination therapy of non-pegylated liposomal doxorubicin (NPLD) and ifosfamide as a first-line treatment has demonstrated promising results for the treatment of advanced/metastatic soft tissue sarcoma (STS), according to results of a Phase 2 clinical trial.
The trial administered 6 cycles of NPLD (50 mg/m²) on day 1, alongside ifosfamide (3000 mg/m² on days 1, 2, and 3 with equidose MESNA), every 3 weeks.
The overall response rate was 40% (95% CI: 0.29-0.51), demonstrating statistical significance. The disease control rate was 81% (95% CI: 0.73-0.90), while only 16% (95% CI: 0.08-0.24) of patients experienced disease progression.
Notably, the combination of NPLD and ifosfamide exhibited limited toxicity.
Buonadonna A, Scalone S, Lombardi D, et al. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers (Basel). 2023;15(20):5036. doi: 10.3390/cancers15205036. PMID: 37894403.